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ABSTRACT
Background: The authors report their initial experience with 
the Memopart™ device (Shanghai Shape Memory Alloy Co Ltd, 
Shanghai, China) for the occlusion of secundum atrial septal 
defect (ASD). Methods: This was a prospective observational 
study of a series of patients undergoing percutaneous occlusion 
of ASD with right ventricle volume overload and favorable 
anatomic characteristics. The procedure was performed by 
percutaneous femoral approach. The mean follow-up was 10.3 
± 5 months, with clinical and 24-hour echocardiographic evalu-
ations (or before hospital discharge), 1, 3, 6, and 12 months 
after implantation. Results: From February/2012 to April/2013, 
21 patients, 16 females, mean age 33.1 ± 18.7 years, were 
submitted to percutaneous occlusion of an ASD. The average 
diameter of the defect was 19.04 ± 6.25 mm and the device 
size was 21.42 ± 6.73 mm (8 to 34 mm). Total occlusion of 
the defect was observed in all cases before hospital discharge. 
During follow-up, all patients were asymptomatic and without 
residual shunt. There was no deaths or any other complica-
tions in the series. Conclusions: The percutaneous closure 
of ASD using a Memopart™ device is an effective and safe 
procedure within the limits of this investigation. The device 
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RESUMO
Oclusão Percutânea de Comunicação Interatrial Tipo 
Ostium Secundum com Prótese Memopart
Introdução: Os autores relatam a experiência inicial da oclu-
são da comunicação interatrial ostium secundum (CIA) com 
a utilização da prótese Memopart (Shanghai Shape Memory 
Alloy Co Ltd, Shanghai, China). Métodos: Estudo prospectivo 
observacional, no qual uma série de pacientes portadores de 
defeitos com significativa repercussão hemodinâmica e car-
acterísticas anatômicas favoráveis ao implante foi submetida 
à oclusão percutânea de CIA. O procedimento foi realizado 
por via femoral percutânea, pela técnica habitual. O período 
de seguimento foi de 10,3 ± 5 meses, com controles clínicos 
e ecocardiográficos 24 horas (ou antes da alta hospitalar), 1, 
3, 6 e 12 meses após o implante. Resultados: No período 
de fevereiro de 2012 a abril de 2013, foram submetidos à 
oclusão percutânea de CIA 21 pacientes, sendo 16 do sexo 
feminino, com idade média de 33,1 ± 18,7 anos. O diâmetro 
médio do defeito foi de 19,04 ± 6,25 mm e o tamanho da 
prótese foi de 21,42 ± 6,73 mm (8 a 34 mm). O implante foi 
realizado com êxito em todos os casos, verificando-se oclusão 
total no controle antes da alta hospitalar. No seguimento, 
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is user-friendly and has a high rate of immediate occlusion, 
even in large defects.
 
 
 
 
 
 
DESCRIPTORS: Heart septal defects, atrial. Septal occluder 
device. Heart defects, congenital. Cardiac catheterization.
O stium secundum atrial septal defect (ASD), located in the oval fossa, constitutes approxi-mately 80% of ASDs.1 Percutaneous occlusion 
should be performed in cases in which the anatomy 
is favorable, when there are hemodynamic repercus-
sions (class I indication, level of evidence B), in as-
sociation with orthodeoxia platypnea syndrome (class 
IIa indication, level of evidence B), or when there is 
a history of paradoxical embolism (class IIa indica-
tion, level of evidence C).2 Approximately 85% of the 
ASDs have essential structural factors that determine 
favorable anatomy for percutaneous occlusion, which 
are: stretched defect diameter < 42 mm, which is the 
maximum diameter of the available prostheses, and 
borders with dimensions ≥ 5 mm, with the exception 
of the aortic or anterosuperior border.
The most commonly used devices for percutaneous 
closure are double-disc nitinol occlusion devices, which 
are self-centering, retrievable, and repositionable; easy 
to handle; and have high success rates in ASD occlu-
sion. These prostheses consist of numerous filaments of 
nitinol (a nickel and titanium alloy), welded at their 
ends and molded to form a central waist, which acts 
as a stent in the communication orifice of two discs, 
a larger left disc and a smaller right disc. The different 
types of this prosthesis vary slightly in relation to the 
nitinol filament thickness, the flaps inserted into the 
discs, their dimensions in relation to the central waist, 
and the device fixation system to the delivery cable.
This study aimed to report the results of a prospec-
tive series of patients undergoing percutaneous closure 
of ASD with the Memopart device (Shanghai Shape 
Memory Alloy Co. Ltda., Shanghai, China).
METHODS
Study design
This was a prospective, longitudinal, and observa-
tional cohort study, performed in a single center, from 
February 2012 to April 2013, of patients submitted to 
percutaneous ASD occlusion using Memopart device. 
The study was performed at the Hemodynamics and 
Interventional Cardiology Laboratory of Hospital das 
Clínicas, Faculdade de Medicina de Ribeirão Preto, 
todos os pacientes estiveram assintomáticos e comprovou-se 
a persistência da oclusão total do defeito. Não houve mor-
talidade e nem outras complicações na série. Conclusões: A 
oclusão percutânea da CIA utilizando-se prótese Memopart 
é um procedimento eficaz e seguro, dentro dos limites desta 
investigação. O implante da prótese é simples e apresenta 
alto índice de oclusão imediata, inclusive de defeitos de 
grandes dimensões.
DESCRITORES: Comunicação interatrial. Dispositivo para 
oclusão septal. Cardiopatias congênitas. Cateterismo cardíaco.
Universidade de São Paulo (HCFMRP-UPS), Brazil and 
was approved by the institution’s ethics committee. All 
patients or their legal guardians signed an informed 
consent after being informed about the purposes of 
the study.
Inclusion criteria
Patients with ASD that participated in the study 
were referred to HCFMRP-USP with the following 
clinical, anatomical, and hemodynamic characteristics: 
weight > 25 kg; dilation of the right cardiac chambers 
visualized during echocardiographic evaluation; QP/
QS ratio > 1.5; pulmonary arterial pressure ≤ 2/3 of 
the systemic level; pulmonary vascular resistance < 5 
UW; defect diameter < 42 mm; defect borders > 5mm, 
except the retroaortic border; signing of the informed 
consent approved by the Institutional Ethics Committee.
Exclusion criteria
Patients with other associated congenital or acquired 
heart diseases, with indication of surgical correction; 
with thin, hypermobile, or deficient ASD borders; those 
with active infection of any kind or infectious process 
in the previous month; patients with hypercoagulable 
syndrome, with contraindication to antiplatelet medica-
tion, were excluded from the study.
PrOSTHESIS
Memopart (Figure 1) is a prosthetic device manu-
factured with filaments of nitinol, a nickel and titanium 
metal alloy at a ratio (in relation to atomic weight) 
of 55% and 45%, respectively. The set of filaments is 
welded together at the ends, forming a bundle that 
has pins at both ends. The bundle is then molded, at 
high temperature, as a double disc of different sizes, 
with a waist in the middle, which acts as a center-
ing mechanism and positions itself in the defect as a 
stent. The pin of the smaller disk, which is the right 
one, has a bolt and nut system, which is screwed into 
the delivery cable. The prosthesis is fixed in delivery 
cable and stretched, to be introduced in the carrier and 
transferred to the delivery sheath. Due to the thermal 
memory of nitinol, the device, when externalized, 
regains its original shape.
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The diameter of the central disk determines the 
size of the device, which ranges from 6 mm to 42 
mm, with 1-mm increments between the sizes from 6 
mm to 20 mm and 2-mm increments between sizes 
22 mm to 42 mm. The technical characteristics of the 
prostheses and releasing sheaths are shown in Table 1.
Procedure
The procedures were performed by femoral ap-
proach under general anesthesia, with transesophageal 
echocardiography. Unfractionated heparin was adminis-
tered at a dose of 100 IU/kg, as well as antimicrobial 
prophylaxis with first-generation cephalosporin. The 
ASD size was determined by static balloon catheter 
technique, and the diameter at which there was flow 
cessation at color Doppler was measured by fluoros-
copy and echocardiography. The implantation technique 
of the double-disc nitinol prostheses has been often 
described by other authors.3,4 Briefly, the prosthesis is 
soaked in saline solution to remove air from the mesh 
and patches; the right disc pin is screwed onto the 
delivery cable; the prosthesis is then inserted into the 
carrier and transferred to the delivery sheath, previously 
positioned in the left superior pulmonary vein. The left 
disk is externalized in the left atrium, near the mouth 
of the pulmonary vein, the delivery sheath is removed 
from the pulmonary vein and the set is subsequently 
retracted, until the disc is anchored in the interatrial 
septum. Keeping the release cable fixed, the sheath is 
withdrawn until the externalization of the right disk. 
After confirming the appropriate position of the device 
in three basic echocardiographic views (short axis, bi-
caval, and four-chamber) and the absence of significant 
residual flow, the prosthesis is released, unscrewing the 
delivery cable by clockwise rotation (Figures 2 and 3).
Several variations of this basic technique are 
sometimes implemented for proper positioning of the 
prosthesis according to the different anatomical ASD 
characteristics. These include the partial opening of 
the waist, before anchoring the left disk; the initial 
approach from the right or left superior pulmonary 
vein; and the partial externalization of the left disk in 
the pulmonary vein, followed by sheath withdrawal to 
the right atrium, in order to impact the right disk first 
in the interatrial septum.5,6 
Procedural success was defined when the prosthesis 
was implanted with proper placement and no residual 
shunt or < 2 mm on transesophageal echocardiogram 
performed during the procedure. 
Follow-up
Patients were evaluated clinically and with trans-
thoracic echocardiography before hospital discharge 
and after one, three, six, and 12 months. They were 
treated during this period with acetylsalicylic acid in 
a single daily dose of 5 mg/kg (maximum dose of 100 
mg/day) for six months. In adult patients, clopidogrel 
was associated, at a dose of 75 mg/day for six months. 
Antibacterial prophylaxis was prescribed, in the event 
of surgical or interventional procedures during the first 
six months of evolution.
Figure 1 – Prosthesis, and set of delivery and release. (A) Schematic representation of the prosthesis: (1) Left disc diameter, (2) Right disc diameter, 
(3) Central disc diameter, (4) Total thickness of the device. (B) Prosthesis discreetly stretched at the proximal and distal ends, showing both the upper 
left and lower right discs, in addition to the central disc. (C) Prosthesis mounted on the delivery system, partially externalized, with the right disk 
still not fully exposed. (D) The different components of the delivery and release system.
A B C
D
Carrier
11/14 cm - PTFE
Dilator
92 cm - PTFE
Delivery sheath
80 cm - PTFE
Hemostatic
valve
Release cable
120 cm - Stainless steel
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Statistical analysis
The continuous variables were described as maximum 
and minimum values, as well as means and standard 
deviations. Categorical variables were described as 
frequencies or percentages.
rESULTS
A total of 21 patients underwent the procedure, 
of whom 16 were females, with mean age of 33.1 ± 
18.7 years and mean weight of 63.0 ± 24.81 kg. Trans-
esophageal echocardiography disclosed the presence 
of single septal defect in all patients, with maximum 
diameter between 7 and 24 mm (14.66 ± 5.1 mm). 
All treated patients had borders > 5 mm, but eight 
patients had deficient or absent aortic border. Clinical, 
echocardiographic and hemodynamic parameters are 
shown in Table 1.
Cardiac showed revealed a mean pulmonary-to- 
systemic flow ratio (QP/QS) of 2.47 ± 1.14, systolic 
pulmonary artery pressure (SPAP) of 35.2 ± 9.5 mmHg, 
and pulmonary arteriolar resistance of 0.9 ± 0.5 UW. 
The ASD diameter measured by balloon-catheter ran-
ged between 7 and 32 mm (19.04 ± 6.25 mm) and 
determined the selection of the prosthesis; a total of 
21 devices were used, varying in size between 8 and 
34 mm (21.42 ± 6.73 mm). 
Implantation was possible in all patients. In two 
patients, it was necessary to position the sheath in the 
right superior pulmonary vein; in one patient, the distal 
portion of the left disc was released inside the pulmonary 
vein and the sheath was withdrawn up to the right disk 
opening, in the right atrium; the set was then pushed and 
anchored in the interatrial septum, and the left disc was 
released from the pulmonary vein, impacting on the left 
side of the septum (30-mm prosthesis).
In all cases, the prosthesis was implanted without 
technical difficulties. In five patients (24%), there was 
minimum residual flow immediately after implantation, 
through the central portion of the prosthesis, which 
disappeared at the control Doppler echocardiography 
prior to discharge. None of the patients needed inten-
sive care and all were discharged on the day after the 
implant. There were no deaths or other periprocedural 
complications in this series. 
During the mean follow-up period, which was 
10.3 ± 5 months, all patients were free of cardiovas-
cular symptoms and the echocardiographic assessment 
showed absence of residual flow. In 18 cases (86%), 
Table 1 
Clinical, echocardiographic, and hemodynamic parameters of patients
Patient
Age 
(years)
Weight 
(Kg) Gender
Atrial septal defect diameter
QP-QS
Prosthesis 
(mm)
Residual flow
Transesophageal 
echocardiogram
Cardiac 
catheterization Immediate
24 
hours
1 8 35 F 7 7 1.5 8 No No
2 45 67 F 8 14 1.9 16 No No
3 35 55 F 18 23 3.3 24 Minimum No
4 3 16 F 14 18 4.8 20 No No
5 15 83 F 13 16 2.6 18 No No
6 20 87 M 12 11 1.7 12 No No
7 75 52 F 6 14 1.9 16 No No
8 37 94 F 24 32 1.9 34 No No
9 47 66 F 15 17 3.0 20 No No
10 9 29 M 10 17 2.9 18 No No
11 54 54 M 20 26 4.6 30 No No
12 41 69 F 15 18 2.7 22 No No
13 57 79 F 17 21 1.9 22 No No
14 9 25 F 16 18 1.8 24 No No
15 27 55 F 15 24 3.0 26 No No
16 29 78 F 20 24 2.6 28 Minimum No
17 39 105 F 10 18 2.0 20 No No
18 44 84 F 21 27 2.5 30 Minimum No
19 51 60 F 10 10 1.6 12 No No
20 12 31 M 13 16 1.7 18 Minimum No
21 38 99 M 24 29 2.7 32 Minimum No
QP/QS = pulmonary flow/systemic flow; F = female; M = male.
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there was normalization of the right ventricle size; in 
three patients, aged > 50 years, there was persistent right 
ventricular dilation; however, with a significant reduc-
tion in its size. There were no late complications such 
as erosion, pericardial effusion, arrhythmias, thrombus 
formation, or infective endocarditis.
DISCUSSION
The literature review disclosed a single series 
published with 73 patients undergoing percutaneous 
closure of ASD using this prosthesis, performed at the 
First People’s Hospital of Yanzhou (China).7 
In this series, the rate of complete occlusion within 
the first 24 hours was 100%. In five patients, minimal 
central residual flow was observed through the implant 
immediately after implantation, which may be explained 
by one of the occlusion mechanisms: the thrombogenic-
ity of polyester flaps and the fact that clotting time of 
patients is variable. This adds to the fact that, during 
the procedure, complete anticoagulation is achieved. 
Complete occlusion was verified in small, moderate, 
and large defects, similarly to cases from published 
studies using nitinol double-disc prostheses.8-13
It is believed that the absence of complications 
was due to the following factors: the prosthesis flex-
ibility, ease of implantation, and accurate selection of 
patients. All patients had optimal anatomic characteristics 
for implant, and borders of appropriate thickness and 
size > 5 mm, with the exception of the anterosuperior 
border, where the graft can be anchored, embracing 
the posterior aspect of the aorta.
The follow-up period of this study is considered 
too short to exclude more severe and at times late-
onset complications, i.e., the erosion of the atrial 
walls with cardiac tamponade or of aortic wall with 
formation of fistula at the left atrium.14-16 However, the 
following precautions were taken when selecting the 
device to reduce the likelihood of this complication: 
prevent prosthesis oversizing, do not implant a device 
with left disk size greater than the maximum length 
of the atrial septum, and even in cases with deficient 
anterosuperior border, anchor the device embracing 
the posterior portion of the aorta, so that the borders 
of the discs, which have a higher erosion potential, 
do not come into contact with the juxtaposition of 
the atrial and aortic walls. 
Figure 2. Atrial septal defect of 16 mm without aortic border: short 
axis (A, B, C and D) and Bicaval or long axis (E, F, G and H). (A and 
E) Diameter of the defect. (B and F) Left-right flow in color Doppler. 
(C and G) Adequate positioning of the prosthesis, embracing the aorta 
in the short axis and the borders of both cavas in the long axis. (D 
and H) No residual flow.
Figure 3. Atrial septal defect (ASD) with no aortic border. (A) Echocar-
diogram in the short axis. (B) Color Doppler showing left-right flow. (C) 
Measuring balloon with discreet waist, determining an ASD diameter 
of 19.5 mm. (D) Color Doppler with the implanted device and the 
absence of residual flow. (E and F) Fluoroscopy in the left anterior 
oblique view of the implanted prosthesis, still attached to the delivery 
cable and under mild tension (C), and released prosthesis showing a 
more vertical position (D). The arrows show the greater separation of 
the disks at the top, where the prosthesis embraces the aorta.
A E
B F
C G
D H
A
C
E F
D
B
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CONCLUSIONS
The Memopart prosthesis has adequate flexibility 
and low profile, and was easy to handle and implant. 
Its use in percutaneous closure of ostium secundum 
ASDs with favorable anatomy was shown to be a safe 
and effective procedure, even in large-size defects 
within the limits of this investigation. A larger series 
with longer follow-up is needed to assess the possible 
occurrence of late-onset complications.
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